PMID- 33419896
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1790-6245 (Electronic)
IS  - 1109-6535 (Print)
IS  - 1109-6535 (Linking)
VI  - 18
IP  - 1
DP  - 2021 Jan-Feb
TI  - Impact of IL-10 Promoter Polymorphisms and IL-10 Serum Levels on Advanced 
      Laryngeal Squamous Cell Carcinoma and Survival Rate.
PG  - 53-65
LID - 10.21873/cgp.20241 [doi]
AB  - BACKGROUND/AIM: Prognosis of advanced stages of laryngeal squamous cell carcinoma 
      (LSCC) remains poor. To clarify therapeutic targets and improve survival rate, 
      identification of new specific and prognostic biomarkers of LSCC is required. The 
      study aimed to evaluate the impact of IL-10:rs1800871, rs1800872, rs1800896 
      single nucleotide polymorphisms (SNPs), and IL-10 serum levels on LSCC 
      development and determine associations of selected SNPs with patient survival 
      rate. PATIENTS AND METHODS: A total of 300 LSCC patients and 533 controls were 
      included in the study. Genotyping was carried out using RT-PCR; IL-10 serum 
      levels were analyzed by ELISA. RESULTS: Significant associations were identified 
      between IL-10 rs1800871 variants and advanced stage of LSCC patient group in the 
      codominant, recessive and additive models (OR=0.473, p=0.027; OR=0.510, p=0.040; 
      and OR=0.733; p=0.037). Significant variants of IL-10 rs1800872 were determined 
      in the codominant, recessive and additive models (OR=0.473, p=0.027; OR=0.510, 
      p=0.040; and OR=0.733, p=0.037). The distribution of IL-10 SNPs genotypes did not 
      impact LSCC patient survival rate (respectively, p=0.952; p=0.952; p=0.991). 
      CONCLUSION: IL-10:rs1800871 and rs1800872 SNPs are associated with advanced stage 
      of LSCC. The genotypic distribution of IL-10 SNPs does not influence the survival 
      rate of LSCC patients.
CI  - Copyright(c) 2021, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Pasvenskaite, Agne
AU  - Pasvenskaite A
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences, 
      Kaunas, Lithuania; agne.pasvenskaite@lsmuni.lt.
FAU - Liutkeviciene, Rasa
AU  - Liutkeviciene R
AD  - Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, 
      Lithuania.
FAU - Gedvilaite, Greta
AU  - Gedvilaite G
AD  - Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, 
      Lithuania.
FAU - Vilkeviciute, Alvita
AU  - Vilkeviciute A
AD  - Neuroscience Institute, Lithuanian University of Health Sciences, Kaunas, 
      Lithuania.
FAU - Liutkevicius, Vykintas
AU  - Liutkevicius V
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences, 
      Kaunas, Lithuania.
FAU - Uloza, Virgilijus
AU  - Uloza V
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences, 
      Kaunas, Lithuania.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Cancer Genomics Proteomics
JT  - Cancer genomics & proteomics
JID - 101188791
RN  - 0 (IL10 protein, human)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Female
MH  - Humans
MH  - Interleukin-10/*blood/*genetics
MH  - Laryngeal Neoplasms/*blood/*genetics/mortality/pathology
MH  - Male
MH  - Polymorphism, Genetic
MH  - Squamous Cell Carcinoma of Head and Neck/*blood/*genetics/mortality/pathology
MH  - Survival Rate
PMC - PMC7796822
OTO - NOTNLM
OT  - IL-10
OT  - Laryngeal squamous cell carcinoma
OT  - gene polymorphism
OT  - levels
OT  - rs1800871
OT  - rs1800872
OT  - rs1800896
OT  - serum
OT  - survival rate.
COIS- The Authors declare no potential conflicts of interest associated with this 
      study.
EDAT- 2021/01/10 06:00
MHDA- 2021/08/21 06:00
PMCR- 2021/01/03
CRDT- 2021/01/09 05:31
PHST- 2020/11/16 00:00 [received]
PHST- 2020/12/02 00:00 [revised]
PHST- 2020/12/17 00:00 [accepted]
PHST- 2021/01/09 05:31 [entrez]
PHST- 2021/01/10 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
PHST- 2021/01/03 00:00 [pmc-release]
AID - 18/1/53 [pii]
AID - 10.21873/cgp.20241 [doi]
PST - ppublish
SO  - Cancer Genomics Proteomics. 2021 Jan-Feb;18(1):53-65. doi: 10.21873/cgp.20241.